Abstract
This review cites clinical evidence demonstrating that nedocromil sodium can reverse the clinical features of airway inflammation in asthma, as shown by decreased bronchial responsiveness, decreased diurnal variation in peak expiratory flow, improved baseline lung function, and a decrease in the frequency and severity of chronic symptoms. Clinical trials have also shown that nedocromil sodium has a statistically significant and clinically relevant effect on daytime and nighttime asthma symptoms within 3 days of starting treatment. On an analysis of relevant trials, the effect on asthmatic cough was significant within 24 hours. This rapid effect on symptoms, together with a reversal of the underlying airways inflammation, is a beneficial combination in the management of asthma.
References
Mar 22, 1979·The New England Journal of Medicine·W M CorraoR S Irwin
Mar 1, 1992·Chest·B CallaghanL Clancy
Jan 1, 1992·Respiration; International Review of Thoracic Diseases·U OreficeA Peratoner
Jul 1, 1992·Respiratory Medicine·A WellsP Thornley
May 1, 1991·The Journal of Allergy and Clinical Immunology·R AalbersJ G de Monchy
Jan 1, 1990·The American Review of Respiratory Disease·E H BelP J Sterk
Mar 1, 1990·The Journal of Allergy and Clinical Immunology·A S RebuckG F MacDonald
Nov 1, 1990·Respiratory Medicine·G D HarperP Ebden
Sep 1, 1989·Chest·J GreifS A Spitzer
Jan 1, 1989·Current Medical Research and Opinion·K C BergmannA Overlack
Nov 1, 1986·Clinical Allergy·P G FyansS S Chatterjee
Jun 1, 1982·Thorax·G RyanF E Hargreave
Oct 1, 1980·Thorax·M R Hetzel, T J Clark
Apr 1, 1995·The Journal of Allergy and Clinical Immunology·P CreticosS Findlay
Feb 1, 1995·The Journal of Allergy and Clinical Immunology·S I WassermanP Steinberg
Jan 1, 1994·The European Respiratory Journal·P W Jones
Jul 1, 1993·The Journal of Allergy and Clinical Immunology·H J SchwartzK C Bergmann